ImmunityBio (IBRX): A Bullish Outlook on the Back of a Revenue Surge

ImmunityBio IBRX caught my attention today, mainly due to its eye-popping 700% revenue surge driven by the rapid adoption of its product, ANKTIVA. This kind of growth is hard to i...